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ABSTRACT
OBJECTIVE: To analyze the prevalence of IgG antibodies to human 
parvovirus B19.
METHODS: Cross-sectional study in a suburban community in São Paulo, 
Southeastern Brazil, between November 1990 and January 1991. Randomly 
selected (N=435) representative samples of sera were collected from healthy 
children older than 15 days old and adults up to 40 years old. IgG antibodies 
were detected using ELISA.
RESULTS: High prevalence of IgG antibodies to B19 parvovirus was found 
in 87% of newborns. The prevalence of maternally derived IgG antibodies 
exponentially plunged up to the 19th month of age. Low prevalence of 
antibodies was found in the fi rst 4 years of life, increasing up to 72% in those 
aged 31-40 years. It was estimated that the average age of fi rst infection in 
this population is 21 ± 7 years old and the optimal age for vaccination with a 
hypothetical vaccine would be 1 year of age.
CONCLUSIONS: Parvovirus B19 IgG antibody prevalence was high in 
newborns and those aged 31–40 years. The analysis by age groups showed a 
pattern similar to that found in previous studies, i.e., low prevalence of infection 
in children that increases with age.
DESCRIPTORS: Parvoviridae Infections, epidemiology. Parvovirus 
B19, Human. Risk Groups. Seroepidemiologic Studies.
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Human parvovirus B19 was fi rst accidentally detected 
in a serum sample of healthy blood donors and until 
recently it has been the only member of the genus Eryth-
rovirus of Parvoviridae family known to be pathogenic 
in humans (Van Regenmortel et al22 2000). B19 virus is 
a small nonenveloped icosahedral capsid with about 25 
nm in diameter and 60 capsomeres containing mainly 
VP2; VP1 accounts for only about 5% of the capsid 
protein. Protein folds are created (alpha) on the surface 
of the assembled capsids where the host’s immune 
system can recognize them as antigenic determinants. 
The B19 virus has a genome that consists of a single-
stranded DNA of 5,596 nucleotides with palindromic 
inverted terminal that repeats at both ends and forms 
hairpin structures (Deiss et al9 1990).
B19 virus has a remarkable tissue-tropism for erythroid 
progenitor cells in human bone marrow (Brown et al5 
1993). It is widespread and infection manifestations 
vary with the host’s immunological and hematological 
status. Cases of B19 virus infection are nearly 30% 
asymptomatic (Brown4 1997).
Acute B19 virus infection is thought to confer a pro-
tective, lifelong immunity (Kajigaya & Momoeda14 
1997). B19 virus infection is common, and 40-60% of 
adults have antibodies against the virus due to previous 
exposure. Epidemiologically, infection rates increase 
every 3–4 years, but there can be longer cycles, with 
RESUMO
OBJETIVO: Analisar a prevalência de anticorpos IgG ao parvovírus humano 
B19.
MÉTODOS: Estudo transversal em uma comunidade de subúrbio de São 
Paulo, Brasil, de novembro 1990 a janeiro de 1991. Amostras aleatórias 
(N=435) e representativas de soro foram coletadas de crianças sadias a partir de 
15 dias de idade e de adultos com até 40 anos. Os anticorpos IgG ao parvovírus 
humano B19 foram detectados pelo teste ELISA.
RESULTADOS: A prevalência de anticorpos IgG ao parvovírus B19 foi de 87% 
dos recém-nascidos. A prevalência de anticorpos IgG de origem materna decaiu 
exponencialmente até o 19o mês de idade. Baixa prevalência de anticorpos foi 
observada nos primeiros quatro anos de vida, aumentando até 72% no grupo 
etário de 31-40 anos. A idade média de aquisição da primeira infecção nesta 
comunidade é de 21 ± 7 anos. A idade ótima para se vacinar as crianças desta 
comunidade com uma vacina hipotética é de um ano de idade. 
CONCLUSÕES: A prevalência de anticorpos IgG ao parvovírus B19 foi alta 
entre recém-nascidos e no grupo etário 31-40 anos. A análise por estrutura etária 
mostrou padrão similar aos estudos prévios relacionados à baixa prevalência 
de infecção em crianças que aumenta com a idade.
DESCRITORES: Infecções por Parvoviridae, epidemiologia. Parvovirus 
B19 Humano. Grupos de Risco. Estudos Soroepidemiológicos.
INTRODUCTION
viral activity increases every 4–7 years (Rodis20 1999). 
B19 virus is usually spread by respiratory secretions, 
but it can be transmitted transplacentally and by blood 
or blood components transfusion (Laub & Strengers15 
2002). This virus has also been established as an im-
portant cause of chronic anemia and thrombopenia in 
immunocompromised hosts (Foto et al10 1993). Infec-
tions during pregnancy may result in severe intrauterine 
anemia that can lead to spontaneous abortion, fetal 
hydrops, or fetal death (Brawn et al6 1984).
In patients younger than fi ve years with fulminating 
hepatitis of unexplained origin, evidence of acute par-
vovirus B19 infection was associated with a distinct 
clinical pattern. In particular, low bilirubin concen-
trations and rapid recovery of liver function without 
transplantation were distinctive features.
The overall prevalence of IgG antibodies to parvovirus 
B19 in healthy adults is 50% in the United States and 
Japan (Anderson et al3 1986); 60%–70% in England 
and Wales (Gay et al12 1994); 44% in Chile (Abarca et 
al1 2002), 44.1% in the Czech Republic (Sodja et al21 
1995), 50% in India (Abraham et al2 2002) and 53.2% 
in Spain (Guerri et al13 2000).
In Brazil and Niger, studies with individuals aged more 
than 10 years old showed a prevalence of IgG antibodies 
of more than 80% (Nascimento et al17 1990). For that 
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reason, a serological investigation was carried out in a 
random sample in a small town located in the outskirts 
of the city of São Paulo, southeastern Brazil.
The objective of the study was to assess parvovirus B19 
serological status in a randomly selected representative 
sample and determine the potential age-specifi c risk of 
susceptibility to reinfection or disease.
METHODS
A cross-sectional study was conducted in the city of 
Caieiras, a northern suburb of the city of São Paulo, 
southeastern Brazil, between November 18, 1990, and 
January 18, 1991, as part of a rubella seroepidemiolo-
gical survey. The sample included healthy subjects up 
to 40 years old. Standard theory (Cochran7 1977) was 
applied to achieve a random, two-level cluster-based 
sample from families randomly selected.
The city of Caieiras (east of the state of São Paulo, 
Brazil) is appropriate for this investigation because its 
inhabitants mostly live , study and work in the city. Its 
urban area coincides with its total population and the 
residences dispersion is absolutely horizontal. Caieiras 
had a population of about 30,000 inhabitants in 1990, 
distributed over an area of 104 km2, mostly (>90%) in 
the urban area (FIBGE11 1980).
Serum samples were collected using a vacuum system 
or butterfl y needle from children under two years of age. 
Sera obtained after centrifugation of clotted samples 
were stored at –20ºC. Age groups of 435 sera samples 
are presented in Table 1. Detailed sera collection, 
demographic information and sampling methods have 
been reported elsewhere (Neto et al18 1994).
Enzyme-linked immunosorbant assay (ELISA – Biotrin 
International, Dublin, Ireland) was used to detect IgG 
antibodies to parvovirus B-19 virus in human serum. Re-
sult interpretation, i.e., whether anti-parvovirus IgG was 
present or not, was based on an estimated cut-off value 
(COV). In the interpretation of absorbances, samples 
with mean absorbance equal to or greater than COV x 
1.1 were considered reactive (positive) and those with 
mean absorbance lower than COV x 0.9 were considered 
non-reactive (negative) to anti-parvovirus B19 IgG.
Children under one year of age who tested positive for 
parvovirus B19 were retested by reverse transcription-
polymerase chain reaction (RT-PCR) analysis. Positive 
RT-PCR samples were excluded from the analysis be-
cause they were naturally (or transplacentally) infected 
with parvovirus B19.
The mathematical and statistical analysis included:
1. - Fitting seroprevalence profi les. The age-dependent 
maternally derived antibodies curve, M(a), was fi tted 
by maximum likelihood techniques to the following 
equation:
M (a) = M(0) exp (–ka) (1)
where M(a) is age-dependent proportion of seroposi-
tives and κ is a fi tting parameter. Therefore, the half-
life of decay of maternally derived antibodies T1/2, is 
given by:
ln(0.5 / M (0))
κ1/2T = −  (2)
where κ is the same as in equation 1. The age-depen-
dent naturally acquired antibodies curve, S+(a), was 
fi tted by the same technique as above to the following 
equation:
S+ (a) =1– exp ae–κ3a + – κ2 (e–κ3a –1) – κ2a
κ1κ3
1
κ3
κ1κ3
(3)
where κι i (i = 1,2,3) are fi tting parameters.
2. Estimating the average age of fi rst infection. The 
average age of fi rst infection, Ā1st, was estimated ac-
cording to the following equation (Coutinho et al8 1993, 
Neto et al 1994,18 199519):
_
A1st =
∞
∫ aS+ (a) da
0
∞
∫ S+ (a) da
0
(4)
where S+(a) is according to equation 3.
3. Estimating the force of infection. The force of infec-
tion, i.e., incidence density, λ, was calculated according 
to the catalytic equation (Massad et al16 1995):
 
λ (a) = (1 – S+ (a))–1 = (ABe–Ba + BCe–Ba + D)dS
+(a)
da
κ1κ3A = ,B = κ3 ,C = (A – D) and D = κ2
1
B
where
(5)
4. Calculating the optimum age for vaccination. There 
is no effective vaccine against human parvovirus B-19 
available yet, but it is just a matter of time. Still, the 
optimum age for vaccination given the seroprevalence 
profi le was estimated. The techniques described in 
Zanetta et al23 2001 were applied. The expression 
related to lifetime expected risk of infection due to 
parvovirus B-19 is given by: 
a∞
∫ 
0
∞c
∫ 
0
E = τ λ u (a')da' +λ u(a')C (a')da' (6)
where λ is the average force of infection, u(a) is the 
fraction of those of age a who are susceptible, τ is a 
normalization constant, and C(a) is vaccine seroconver-
sion. Since the latter is unknown, it was taken as the 
complement of M(a), the maternally derived antibody 
function.
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Considering that a proportion p of the population is 
vaccinated at age av, the proportion of remaining sus-
ceptible persons, u(a), is then
0 < a < ac
ac < a < av ,
a > av
u (a) = exp [– λ (a – ac)]
1 – M (a)
[1 – pC (a)]e–λ(a–ac),
if av > ac (7)
or
0 < a < ac
ac < a < av ,
u (a) =
1 – M (a)
exp [– λ (a – ac)]
 if av < ac (8)
where ac is a critical age up to which maternal antibod-
ies protect the child.
The average force of infection λ,was calculated accord-
ing to equation 4, since it is the inverse of the average 
age of fi rst infection (Coutinho et al8 1993, Neto et al 
1994,18 199519). The optimum age of vaccination was 
obtained by evaluating the age of vaccination that 
minimizes E, as in equation 6.
RESULTS
The Table summarizes the seroepidemiological analy-
sis, by age groups, with a 95% confi dence interval.
There are two phases of inverse behaviors. In the fi rst 
phase, from newborns to children aged 16–19 months, 
the proportion of seropositives decreases. There was a 
fast decline in maternal antibody after the fi rst month of 
age, with the highest proportion of infants seronegative 
for parvovirus B19 between 16 and 19 months of age. 
In the second phase, from children aged 20 months to 
adults older than 40 years old, there is a progressive 
increase in the proportion of seropositives immune to 
parvovirus B19. In this phase, the seropositive propor-
tion increases fl atly with age, so that 53.85% develop 
immunity between 23 and 30 years of age.
A comparative analysis was performed in seropositive 
subjects and they were divided into six age groups: <1 
month, 1–4 months, 5–19 months, 20–48 months, 5–30 
years, 31–40 years, as shown in Figure 1.
There was found 87% prevalence of IgG antibodies 
anti-parvovirus B19 in infants under 15 days. Also, 
there was seen a decrease in seropositives as from the 
fi rst month of life and an increase as from fi ve years up 
to 40 years of age. In the latter age group, prevalence 
was 72.7%. The chi-square test showed signifi cant 
differences in the proportions of seropositive in high 
prevalence age groups (p<0.0001, df=5). When differ-
ences among proportions of seropositive subjects in low 
prevalence age groups (1–4 months, 5–19 months and 
20–48 months) were checked using the chi-square test, 
no signifi cant differences were seen (p=0.278).
After establishing the proportion of seropositive at 
each age group (Table), data were fi tted to two continu-
ous functions by the maximum likelihood technique, 
one for the maternally derived antibody decay phase, 
M(a), and the other for naturally acquired infection 
phase, S+(a).
In the maternal antibody decay phase, M(a) was fi tted 
to an exponential curve as in equation 1. Estimations 
were made using the regression module for SPSS 
pack version 10.0. The half-life of maternally derived 
antibody decay, T1/2, was 0.093 months, a very rapid 
decay. Figure 1 shows the curve M(a) adjusted to the 
decay phase.
A rapid decay of maternally derived antibodies was seen 
in the fi rst month, alternating slow decays and increases 
from the 12th up to the 14th month. Between the 14th and 
the 19th month there were only decays up to complete 
elimination of motherly antibodies.
For scheming the ascending phase of naturally acquired 
infection, S+(a) was fi tted to equation 3, as shown in 
Figure 2.
The arrow points to the average age of fi rst infection, 
calculated according to equation 4 in 21 ± 7 years of age, 
a very high average age of fi rst infection acquisition.
Figure 1. Maternally derived antibodies stratifi ed by age. 
Caieiras, Southeastern Brazil, 1990–1991.
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Figure 2. Ascending phase of naturally acquired infection, 
S+(a). The arrow indicates the average age of fi rst infection. 
Caieiras, Southeastern Brazil, 1990–1991.
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Figure 3 shows the age-dependent force of infection, 
calculated according to equation 5.
The force of infection dropped quickly from the age 
of one onwards, stabilizing at low levels after the age 
of ten. The average force of infection was 0.047 new 
cases per susceptible per year, which in turn resulted 
in an estimated very high average age of fi rst infection 
acquisition of 21 years.
Figure 4 shows the optimal age to vaccinate children 
against parvovirus B19.
Regardless of vaccine coverage, the age that minimized 
the expected lifetime risk of infection was one year (ar-
row). Such younger age may be an unexpected result 
since fi rst infection on average occurs at an older age. 
However, as shown in Figure 3, the mass of the force 
of infection distribution is concentrated at younger 
ages, implying that the virus is probably circulating 
among the youngsters.
Figure 4. Optimal age for children vaccination for infection 
control at 3 different levels of vaccine coverage (50%, 70% 
and 90%). Caieiras, Southeastern Brazil, 1990–1991.
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Figure 3. Age-dependent force of infection. Caieiras, South-
eastern Brazil, 1990–1991.
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Table. Parvovirus B19 seroprevalence in subjects aged 0–40, stratifi ed by age group. Caieiras, Southeastern Brazil, 
1990–1991.
Age group 
(months [m] or years [y])
Number of individuals Proportion of 
positive
95% CI
Seropositive Seronegative Total
<1 m 7 1 8 0.875 0.65;1.00
1–2 m 4 12 16 0.25 0.04;0.46
3–4 m 4 15 19 0.2105 0.03;0.39
5–6 m 4 23 27 0.1481 0.01;0.28
7–8 m 6 40 46 0.1304 0.03;0.23
9–10 m 3 27 30 0.10 0.00;0.21
11–12 m 4 18 22 0.1818 0.02;034
13–15 m 3 12 15 0.20 0.00;0.40
16–19 m 0 19 19 0.00 0.00;0.00
20–23 m 3 17 20 0.15 0.00;0.31
2 y 4 41 45 0.0889 0.01;0.17
3 y 8 33 41 0.1951 0.073;0.32
4 y 3 24 27 0.1111 0.00;0.23
5 y 4 10 14 0.2857 0.05;0.52
6–11 y 19 16 35 0.5429 0.38;0.71
12–16 y 4 7 11 0.3636 0.08;0.65
17–22 y 7 9 16 0.4375 0.20;0.68
23–30 y 7 6 13 0.5385 0.27;0.81
31–40 y 8 3 11 0.7273 0.32;1.00
Total 102 333 435 0.2345
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DISCUSSION
Epidemiologically, there can be made considerations 
based on the profi le found in the present study. A major 
fi nding is the high proportion of motherly derived par-
vovirus B19 antibodies at birth (Figure 1), revealing that 
the great majority of childbearing women already had 
been infected, and evidencing that antibodies cross the 
placenta due to IgG active transplacental transport.
Possibly high levels of IgG may be explained by facili-
tating mechanisms for newborn protection over a longer 
period of time by means of immunity acquired during 
gestation. Immunoglobulin mother-fetus transference 
has been reported during pregnancy indicating that 
human placenta develops a specifi c IgG mechanism 
of transference.
As from the fi rst month of life, the proportion of sero-
positive individuals declined every month up to the age 
of 16 months, when IgG antibodies against parvovirus 
B19 were no longer detected in children. The immune 
status lasted up to the 19th month of life (Figure 1). The 
half-life of maternally derived antibody decay, T1/2, was 
0.093 months, which is a rapid decay. This motherly-
derived antibodies loss in children changes in the same 
fashion as in England, and in children younger than 12 
months, there are decreasing levels of IgG motherly-
derived antibodies to B19.10
The serological profi le in this community also indi-
cates that B19 infection rates are low before the age 
of fi ve, being slow between one and four years of age. 
This can be explained by apparently low exposure 
between susceptible and infected individuals in these 
age groups. As from the age of fi ve, the proportion of 
infected individuals grows fast, declining slowly after 
16 years of age (36.4%, Figure 1), which results in 
high susceptibility during childbearing years between 
the age of 16 and 30 years with intense viral activity 
in these age groups.
Increased antibody prevalence (Figure 4) is possibly due 
to infection. As from the age of 20 months, exposure to 
B19 virus is frequent and the proportion of individuals 
with detectable antibodies increases fl atly. Despite varia-
tions, there was seen an increasing trend in the propor-
tion of seropositive individuals as age increases.
The continuous growth in the proportion of seroposi-
tive individuals during adult life evidences that new 
exposure and possibly B19 reinfection were relatively 
frequent, infecting a signifi cant proportion of adults 
and disseminating the virus. The high IgG prevalence 
in adults resulted in high motherly derived antibody 
acquisition by a large proportion of newborn children. 
In spite of the low immunity prevalence, which also 
implies a low incidence of disease, this was observed 
in Japan during different epidemic cycles.20
The fact that the force of infection drops very quickly 
from the age of one onwards, stabilizing after the age 
of 10 at very low levels results in very high average 
age of fi rst infection acquisition, at an estimated age 
of 21 years.
Finally, although there is no effective vaccine available 
against human parvovirus B19, the optimal age for 
vaccination in this community was estimated. The age 
that minimizes the expected lifetime risk of infection 
is one year. Such younger age is probably due to the 
fact that the mass of the force of infection distribution 
is concentrated at younger ages, implying that the virus 
is probably circulating among the youngsters.
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